Toggle light / dark theme

The Achilles heel of the influenza virus: Ubiquitin protein may be an approach for future medicines

Influenza viruses are becoming increasingly resilient to medicines. For this reason, new active ingredients are needed. Important findings in this regard have been provided by researchers at the University of Münster: for the virus to proliferate, the polymerase of the influenza A virus has to be modified many times through enzymes in the host cells.

The team of researchers was able to produce a comprehensive map of the types of modification. Medicines directed against the enzymes would be resilient to rapid mutations in the virus, thus offering great potential for the future. The study results have now been published in the journal Nature Communications.

Every year, the influenza season presents a challenge to hospitals. Despite having been vaccinated, and patients with run a heightened risk of falling prey to a severe bout of influenza. What is especially insidious about is their ability to mutate rapidly, which makes them increasingly resilient to medicines. For this reason, there is an urgent need for new active ingredients in order to be able to continue providing effective treatment for the illness in future.

How the influenza virus achieves efficient viral RNA replication

New insights on how subunits of the influenza virus polymerase co-evolve to ensure efficient viral RNA replication are provided by a study published October 3 in the open-access journal PLOS Pathogens by Nadia Naffakh of the Institut Pasteur, and colleagues. As the authors note, the findings could lead to novel strategies for antiviral drug development.

Because of their yearly recurrence and the occasional emergence of pandemics, influenza viruses represent a worldwide major public health threat. Enhancing fundamental knowledge about the influenza RNA–, which is an enzyme that consists of three subunits (i.e., a heterotrimer) and ensures transcription and of the viral genome, is essential to reach the goal of better prevention and treatment of disease.

In the new study, Naffakh and colleagues gained new insights into viral polymerase function. They showed that the polymerase subunits co-evolve to ensure not only optimal inter-subunit cooperation within the heterotrimer, but also proper levels dimerization—the process by which pairs of heterotrimers attach together—which appears to be essential for efficient viral RNA replication. The findings point to polymerase dimerization as a feature that can restrict genetic reassortment, a major evolutionary mechanism in which swap gene segments, and could become an attractive target for antiviral drug development.

VKORC1 single nucleotide polymorphisms in rodents in Spain

Rodents are considered one of the animal pests with the greatest impact on agricultural production and public health, especially the brown or Norway rat (Rattus norvegicus), the black or roof rat (Rattus rattus) and the house mouse (Mus musculus). Its control is an increasing problem worldwide. The intensification of agricultural production methods as well as the increase in merchandise transport to sustain growing populations is leading to an increase in waste production causing the growth of these rodent populations. The estimated losses in crop production caused by rodents range from between 5% and 90% (Stenseth et al., 2003) and this can cause problems in food security during harvesting (Belmain et al., 2015). Other negative impacts result from some rodent species living very close to human environments that can have a direct influence not only on human health through potential transmission of gastroenteric diseases and zoonosis to householders but also on domestic livestock. Therefore, rodent pest control is crucial and nowadays, the only effective control method available is the use of anticoagulant rodenticides (ARs).

ARs are so named because they interfere with the blood coagulation processes. The processes of activating various coagulation factors depends on the amount of vitamin K in its reduced form that exists in the organism. ARs inhibit the enzyme vitamin K 2,3-epoxide reductase (VKORC1) that is responsible for reducing vitamin K and maintaining the balance between its oxidized and reduced forms. The inhibition of VKORC1 prevents the activation of the coagulation factors resulting in animal death by internal bleeding. However, the intensive use of ARs can cause rodents to lose their susceptibility and become resistant to them. Genetic resistances to ARs are mainly associated with mutations or single nucleotide polymorphisms (SNPs) in the gene that codes for VKORC1 (vkorc1), causing amino acid substitutions in the VKORC1 protein ( Pelz et al., 2005 ). There are studies on this topic in several countries of central and northern Europe detecting rodent populations resistant to AR. Currently, there are at least 13 mutations mainly located in the exon 3 of the vkorc1 gene described in various countries of the European Union that confer resistance to specific ARs ( Berny et al., 2014 ; Goulois et al., 2017 ). In Eastern and Southern European countries, the information on the incidence of resistances to rodenticides is scarce, and it is becoming increasingly important to generate information on this subject ( Berny et al., 2014). In Spain, a mice population at the coastal countryside showing an adaptive introgression between house mouse and Algerian mouse that confers anticoagulant resistance has been described ( Song et al., 2011 ). While recently, four VKORC1 mutations in black rat were found in Toledo, Segovia and Zaragoza ( Goulois et al., 2016 ; Damin-Pernik et al., 2022 ). Any increase in resistant in rodent populations would lead to pest control issues that may causing serious agricultural, farming and public health problems.

Scientific advances have revolutionized the study of anticoagulant resistances in terms of understanding their genetic basis, physiological mechanisms and geographical distribution. The techniques based on the extraction and partial sequencing of genomic DNA allow a fast and precise monitoring of possible genetic resistances. Most of these tests involve laboratory studies using live rodents or blood samples taken from animals in the field. However, the improvement of DNA extraction techniques now allows the analysis of faecal samples (stool), increasing the number of samples that can be taken without the need for sampling by trapping or the management of dead animals (Meerburg et al., 2014). The importance of initial detection of genetic resistances due to mutations is crucial. The hypothesis of work, presenting it as a null hypothesis, is that there will be no rodent mutations in the vkorc1 gene in Spain.

Researcher develops new methods to measure ‘forever chemicals’ in both the atmosphere and in aerosol particles

From regulators to researchers and most industries in between, all eyes are on PFAS, per-and polyfluoroalkyl substances, are a class of highly fluorinated human-made compounds that have been used for decades in everything from nonstick cookware and personal care products to fire-fighting foams and school uniforms. Their commonality and extreme resistance to environmental degradation has made them ubiquitous in ground water, soil, and worst of all humans. Linked to a slew of health risks including liver toxicity, bladder cancer, and decreased immune response to vaccinations, exposure to PFAS is concerning. So, how can we eliminate these “forever chemicals?”

Historically, PFAS substances have only been characterized in water and soil, but the emission of these compounds during chemical manufacturing, use, and disposal results in their emission into the air. Ryan Sullivan, Professor of Mechanical Engineering and Chemistry at Carnegie Mellon University, has been developing new methods to measure PFAS in both the atmosphere and in aerosol particles to answer outstanding questions regarding PFAS atmospheric components that lead to human exposure. His group is also developing new approaches to destroy forever molecules that are not removed by conventional water treatment plants.

The research is published in the journal Environmental Science: Processes & Impacts.

New testing approach diagnoses COVID-19 with near-perfect accuracy

Most existing COVID-19 tests “rely on the same principle, which is that you have accumulated a detectable amount of viral material, for example, in your nose,” says study lead author Frank Zhang, who worked on the project as a Flatiron research fellow at the Flatiron Institute’s Center for Computational Biology (CCB) in New York City. “That poses a challenge when it’s early in the infection time window and you haven’t accumulated a lot of viral material, or you’re asymptomatic.”

The new technique is instead based on how our bodies mount an when invaded by SARS-CoV-2, the virus that causes COVID-19. When the assault starts, specific genes turn on. Segments of those genes produce mRNA molecules that guide the building of proteins. The particular blend of those mRNA molecules changes the types of proteins produced, including proteins involved in virus-fighting functions. The new method can confidently identify when the body is mounting an immune response to the COVID-19 virus by measuring the relative abundance of the various mRNA molecules. The new study is the first to use such an approach to diagnose an infectious disease.

Study supports the concept of atherosclerosis as a T-cell autoimmune disease targeting the arterial wall

In a recent study published in Nature Cardiovascular Research, researchers assessed T-cell tolerance checkpoints observed in atherosclerosis.

Atherosclerosis is a chronic inflammatory disease of the arteries. It is characterized by the presence of atherosclerotic plaque present in the inner layer of arteries. Plaques that rupture result in strokes or heart attacks. Significant innate immune cells that contribute to atherosclerosis have been identified.

In addition, certain subtypes of T cells, such as CD4+ regulatory T (Treg) cells and CD8+ T cells, promote or suppress the illness in mice. Yet, fundamental problems regarding T cell immunity noted in atherosclerosis are unanswered. In particular, it is unknown whether T cell responses linked with atherosclerosis are incident in the circulation.

First-of-its-kind gecko robot could one day help doctors in surgeries

“Nature is a great source of inspiration, and nanotechnology is an exciting way to apply its lessons.”

A small robot that could one day help doctors perform surgery was inspired by the incredible grasping ability of geckos and the efficient motion of inchworms.

What is GeiwBot, the soft robot in healthcare?


University of Waterloo.

The new robot, created by engineers at the University of Waterloo, moves on any surface-even up walls and over ceilings-by tapping into the ultraviolet (UV) light and magnetic force technologies. Better yet, it’s the first of its kind to operate without an external power source, allowing for remote control and versatility in hard-to-reach areas.

New cell therapy for chronic heart failure actually works, here is how

The new development is promising a potential treatment option for patients with chronic heart failure.

There are over six million patients in the U.S. who suffer from chronic heart failure, and now there is a cell therapy that might help all these patients.

They have proposed a treatment called MPC (mesenchymal precursor cell) therapy.


Rasi Bhadramani/iStock.

A team of researchers from the Texas Health Institute (THI) recently published results of the biggest cell therapy trial conducted in 565 heart patients from 51 different cities in the U.S. (also referred to as DREAM HF trials).

AI, An Amplifier Of Human Intelligence

I attended Celesta Capital’s TechSurge Summit on February 13, 2023 at the Computer History Museum. In this piece I will talk about interview with Nic Brathwaite Founder and Managing Partner of Celesta Capital as well as Sriram Viswanathan (Founding General Manager of Celesta and heavily involved in venture investments in India), and a panel discussion by John Hennessy (Chairman of Alphabet).

In a companion article I will talk about my interview with John Hennessy, Chairman of Alphabet (Google’s parent company) and Vint Cerf, also with Google, during the TechSurge Summit.


He also said that the current cost of inference is too high and that Chat GBT is too often busy. He thought that there were opportunities to build AI systems trained and focused on particular uses, which would lead to smaller models and they would be more practical. He thought we are 1–2 years away from useful products, particularly in business intelligence. He also said that the use of AI allows us to program with data rather than lots of lines of code. Google was hesitant to produce something like Chat GBT, they didn’t want the system to say wrong or toxic things. He said that the tech industry needs to be more careful to encourage a civil society and that many tools, such as the Internet, were not anticipated to be used to do evil things.

John said that AI can be an amplifier of human intelligence. It could be used to help teach kids in a classroom with customized instruction to match their rate and type of learning. He said that the chance of making a true general AI is much more likely than it was in the past. He also made comments on defensive technologies, blockchain, fighting climate change, the future of semiconductor technology in the US and medical innovations.

Celesta’s TechSurge Summit covered investment trends in deep technology and included insights on data growth and demand. John Hennessy, CEO of Alphabet, covered many topics, including how AI can be an amplifier of human intelligence.